Summary
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M
patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC
Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC
Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190151672 |
| Start date: | 01-01-2022 |
| End date: | 30-06-2024 |
| Total budget - Public funding: | 3 537 295,00 Euro - 2 476 106,00 Euro |
Cordis data
Original description
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65Mpatients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC
Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
